{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:05:47Z","timestamp":1751601947638,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19767","22K09703"],"award-info":[{"award-number":["24K19767","22K09703"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Secretory carcinomas (SCs) of the salivary gland have recently been recognized as low-grade, malignant tumors. Before this designation, most SCs were diagnosed as variants of acinic cell carcinomas (AciCCs). SCs harbor the t(12;15)(p13;q25) translocation that generates an oncogenic fusion gene, <jats:italic>ETS variant transcription factor 6\/Neurotrophic tyrosine receptor kinase(ETV6::NTRK3)<\/jats:italic>. However, detecting fusion genes in a clinical setting is time-consuming and costly. In this study, we examined 31 cases previously diagnosed as AciCC and SC using pathological analyses with detection of fusion genes using <jats:italic>ETV6<\/jats:italic> break-apart fluorescence in-situ hybridization and reverse transcription-polymerase chain reaction. After re-analysis, we found that these 31 cases actually comprised 21 SCs and 10 AciCCs. We examined the diagnostic utility of immunohistochemistry by comparing results with the fusion gene, Pan-Trk, which despite having recently been reported as effective for diagnosis of SC, was not universally accurate. However, combining mammaglobin and S-100 could be particularly useful in diagnosing SC. This practical method will contribute to accurate diagnosis of SCs, while saving time in daily clinical practice.<\/jats:p>","DOI":"10.1007\/s12672-025-03072-3","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:57:06Z","timestamp":1751540226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical pathological methods for reliable diagnosis of secretory carcinomas of the salivary gland"],"prefix":"10.1007","volume":"16","author":[{"given":"Ryo","family":"Kawaura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Hanamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Usubuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ohkoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Katori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenori","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"3072_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/pas.0b013e3181d9efcc","volume":"34","author":"A Sk\u00e1lov\u00e1","year":"2010","unstructured":"Sk\u00e1lov\u00e1 A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599\u2013608. https:\/\/doi.org\/10.1097\/pas.0b013e3181d9efcc.","journal-title":"Am J Surg Pathol"},{"key":"3072_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.humpath.2014.09.012","volume":"46","author":"M Urano","year":"2015","unstructured":"Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol. 2015;46:94\u2013103. https:\/\/doi.org\/10.1016\/j.humpath.2014.09.012.","journal-title":"Hum Pathol"},{"key":"3072_CR3","volume-title":"WHO classification of head and neck tumours","author":"AKCJ El-Naggar","year":"2017","unstructured":"El-Naggar AKCJ, Grandis JR, Takata T, Slootweg PJ. WHO classification of head and neck tumours. 4th ed. Lyon: IARC; 2017.","edition":"4"},{"key":"3072_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/pas.0b013e3181a38e1c","volume":"33","author":"A Sk\u00e1lov\u00e1","year":"2009","unstructured":"Sk\u00e1lov\u00e1 A, Sima R, Vanecek T, Muller S, Korabecna M, Nemcova J, et al. Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2\/neu genes. Am J Surg Pathol. 2009;33:1137\u201345. https:\/\/doi.org\/10.1097\/pas.0b013e3181a38e1c.","journal-title":"Am J Surg Pathol"},{"key":"3072_CR5","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.anl.2019.10.003","volume":"47","author":"Y Numano","year":"2020","unstructured":"Numano Y, Ogawa T, Ishikawa T, Usubuchi H, Nakanome A, Ohkoshi A, et al. Parotid secretory carcinoma with high-grade transformation. Auris Nasus Larynx. 2020;47:1043\u20138. https:\/\/doi.org\/10.1016\/j.anl.2019.10.003.","journal-title":"Auris Nasus Larynx"},{"key":"3072_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/pas.0000000000000972","volume":"42","author":"A Sk\u00e1lov\u00e1","year":"2018","unstructured":"Sk\u00e1lov\u00e1 A, Vanecek T, Martinek P, Weinreb I, Stevens TM, Simpson RHW, et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol. 2018;42:234\u201346. https:\/\/doi.org\/10.1097\/pas.0000000000000972.","journal-title":"Am J Surg Pathol"},{"key":"3072_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.humpath.2018.08.011","volume":"83","author":"J Guilmette","year":"2019","unstructured":"Guilmette J, Dias-Santagata D, Nos\u00e9 V, Lennerz JK, Sadow PM. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum Pathol. 2019;83:50\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2018.08.011.","journal-title":"Hum Pathol"},{"key":"3072_CR8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.ccr-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK Fusion-Positive solid tumors. Clin Cancer Res. 2022;28:1302\u201312. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-3597.","journal-title":"Clin Cancer Res"},{"key":"3072_CR9","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1093\/oncolo\/oyac080","volume":"29","author":"X Le","year":"2022","unstructured":"Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE, et al. Larotrectinib treatment for patients with TRK Fusion-Positive salivary gland cancers. Oncologist. 2022;29:e779\u201388. https:\/\/doi.org\/10.1093\/oncolo\/oyac080.","journal-title":"Oncologist"},{"key":"3072_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/annonc\/mdw042","volume":"27","author":"A Drilon","year":"2016","unstructured":"Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27:920\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdw042.","journal-title":"Ann Oncol"},{"key":"3072_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/s1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of Selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 2022;23:1261\u201373. https:\/\/doi.org\/10.1016\/s1470-2045(22)00541-1.","journal-title":"Lancet Oncol"},{"key":"3072_CR12","doi-asserted-by":"publisher","first-page":"105370","DOI":"10.1016\/j.oraloncology.2021.105370","volume":"119","author":"Y Pang","year":"2021","unstructured":"Pang Y, Sun L, Liu H, Ma J. Differential diagnosis and treatment of salivary secretory carcinoma and acinic cell carcinoma. Oral Oncol. 2021;119:105370. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105370.","journal-title":"Oral Oncol"},{"key":"3072_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00428-015-1786-8","volume":"467","author":"MS Hsieh","year":"2015","unstructured":"Hsieh MS, Chou YH, Yeh SJ, Chang YL. Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland. Virchows Arch. 2015;467:145\u201353. https:\/\/doi.org\/10.1007\/s00428-015-1786-8.","journal-title":"Virchows Arch"},{"key":"3072_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/pas.0000000000000537","volume":"40","author":"A Sk\u00e1lov\u00e1","year":"2016","unstructured":"Sk\u00e1lov\u00e1 A, Vanecek T, Simpson RH, Laco J, Majewska H, Baneckova M, et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol. 2016;40:3\u201313. https:\/\/doi.org\/10.1097\/pas.0000000000000537.","journal-title":"Am J Surg Pathol"},{"key":"3072_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2012.04232.x","author":"SI Chiosea","year":"2012","unstructured":"Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012;61. https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04232.x.:387\u2013\u200994."},{"key":"3072_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/modpathol.2015.64","volume":"28","author":"TM Stevens","year":"2015","unstructured":"Stevens TM, Kovalovsky AO, Velosa C, Shi Q, Dai Q, Owen RP, et al. Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. Mod Pathol. 2015;28:1084\u2013100. https:\/\/doi.org\/10.1038\/modpathol.2015.64.","journal-title":"Mod Pathol"},{"key":"3072_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/pas.0b013e318231542a","volume":"36","author":"A Connor","year":"2012","unstructured":"Connor A, Perez-Ordo\u00f1ez B, Shago M, Sk\u00e1lov\u00e1 A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012;36:27\u201334. https:\/\/doi.org\/10.1097\/pas.0b013e318231542a.","journal-title":"Am J Surg Pathol"},{"key":"3072_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.anndiagpath.2016.04.003","volume":"22","author":"NU Din","year":"2016","unstructured":"Din NU, Fatima S, Kayani N. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic study of 11 cases. Ann Diagn Pathol. 2016;22:49\u201353. https:\/\/doi.org\/10.1016\/j.anndiagpath.2016.04.003.","journal-title":"Ann Diagn Pathol"},{"key":"3072_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40463-018-0315-6","volume":"47","author":"D Forner","year":"2018","unstructured":"Forner D, Bullock M, Manders D, Wallace T, Chin CJ, Johnson LB, et al. Secretory carcinoma: the Eastern Canadian experience and literature review. J Otolaryngol Head Neck Surg. 2018;47:69. https:\/\/doi.org\/10.1186\/s40463-018-0315-6.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"3072_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.prp.2017.07.017","volume":"213","author":"F Baghai","year":"2017","unstructured":"Baghai F, Yazdani F, Etebarian A, Garajei A, Skalova A. Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin. Pathol Res Pract. 2017;213:1112\u20138. https:\/\/doi.org\/10.1016\/j.prp.2017.07.017.","journal-title":"Pathol Res Pract"},{"key":"3072_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/pas.0000000000000911","volume":"41","author":"JF Hechtman","year":"2017","unstructured":"Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41:1547\u201351. https:\/\/doi.org\/10.1097\/pas.0000000000000911.","journal-title":"Am J Surg Pathol"},{"key":"3072_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00428-019-02640-7","volume":"476","author":"D Bell","year":"2020","unstructured":"Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, et al. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020;476:295\u2013305. https:\/\/doi.org\/10.1007\/s00428-019-02640-7.","journal-title":"Virchows Arch"},{"key":"3072_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12070-023-04127-z","volume":"76","author":"G Sharma","year":"2024","unstructured":"Sharma G, Kamboj M, Narwal A, Keerthika R, Devi A, Vijayakumar G. Diagnostic utility of expression pattern of S100\/Mammaglobin\/SOX10\/DOG 1 immunohistochemistry in differentiation of secretory and acinic cell carcinoma: A systematic review and Meta-Analysis. Indian J Otolaryngol Head Neck Surg. 2024;76:208\u201318. https:\/\/doi.org\/10.1007\/s12070-023-04127-z.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"3072_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jasc.2022.07.001","volume":"11","author":"V Krishnan","year":"2022","unstructured":"Krishnan V, Nguyen L, Shen R, Lieu D, De Peralta-Venturina M, Fan X. NOR-1 (NR4A3) immunostaining on cytologic preparations for the preoperative diagnosis of acinic cell carcinoma of the salivary gland. J Am Soc Cytopathol. 2022;11:352\u20138. https:\/\/doi.org\/10.1016\/j.jasc.2022.07.001.","journal-title":"J Am Soc Cytopathol"},{"key":"3072_CR25","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/pas.0000000000001494","volume":"44","author":"F Haller","year":"2020","unstructured":"Haller F, Moskalev EA, Kuck S, Bieg M, Winkelmann C, M\u00fcller SK, et al. Nuclear NR4A2 (Nurr1) immunostaining is a novel marker for acinic cell carcinoma of the salivary glands lacking the classic NR4A3 (NOR-1) upregulation. Am J Surg Pathol. 2020;44:1290\u20132. https:\/\/doi.org\/10.1097\/pas.0000000000001494.","journal-title":"Am J Surg Pathol"},{"key":"3072_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00428-019-02600-1","volume":"475","author":"MS Hsieh","year":"2019","unstructured":"Hsieh MS, Jeng YM, Lee YH. Mist1: a novel nuclear marker for acinic cell carcinoma of the salivary gland. Virchows Arch. 2019;475:617\u201324. https:\/\/doi.org\/10.1007\/s00428-019-02600-1.","journal-title":"Virchows Arch"},{"key":"3072_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.canep.2014.07.014","volume":"38","author":"T Tamaki","year":"2014","unstructured":"Tamaki T, Dong Y, Ohno Y, Sobue T, Nishimoto H, Shibata A. The burden of rare cancer in japan: application of the RARECARE definition. Cancer Epidemiol. 2014;38:490\u20135. https:\/\/doi.org\/10.1016\/j.canep.2014.07.014.","journal-title":"Cancer Epidemiol"},{"key":"3072_CR28","unstructured":"Institute NC, SEER Cancer Statistics Review (CSR.) 1975\u20132018. In: Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editor.2021. https:\/\/seer.cancer.gov\/csr\/1975_2018\/. Accessed 23 April 2025."},{"key":"3072_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/nop\/npad081","volume":"11","author":"LP Priesterbach-Ackley","year":"2024","unstructured":"Priesterbach-Ackley LP, van Kuik J, Tops BBJ, Lasorella A, Iavarone A, van Hecke W, et al. RT-PCR assay to detect FGFR3::TACC3 fusions in formalin-fixed, paraffin-embedded glioblastoma samples. Neurooncol Pract. 2024;11:142\u20139. https:\/\/doi.org\/10.1093\/nop\/npad081.","journal-title":"Neurooncol Pract"},{"key":"3072_CR30","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/pas.0000000000001535","volume":"44","author":"A Sk\u00e1lov\u00e1","year":"2020","unstructured":"Sk\u00e1lov\u00e1 A, Bane\u010dkova M, Thompson LDR, Pt\u00e1kov\u00e1 N, Stevens TM, Brcic L, et al. Expanding the molecular spectrum of secretory carcinoma of salivary glands with a novel VIM-RET fusion. Am J Surg Pathol. 2020;44:1295\u2013307. https:\/\/doi.org\/10.1097\/pas.0000000000001535.","journal-title":"Am J Surg Pathol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03072-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03072-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03072-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:57:08Z","timestamp":1751540228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03072-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3072"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03072-3","relation":{"references":[{"id-type":"doi","id":"10.1111\/j.1365-2559.2012.04232.x","asserted-by":"subject"}]},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participation in the study was voluntary, and verbal and written informed consent were obtained before enrollment. This study was approved by the ethics committees of Tohoku University Graduate School of Medicine (#2019-1-082) and Gifu University Graduate School of Medicine (#2022-124). Consent for publication was obtained for every person whose data are included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1254"}}